We have recently isolated and characterized a human monoclonal autoantibody, MOR-hl (multiple organ-reactive human 1), that reacts with antigens in multiple organs and have shown that this antibody binds to human growth hormone and a 35,000-mol wt protein. In the present study we generated three monoclonal antiidiotypic antibodies (4E6, 3E5, and 3F6) against MOR-hl. These anti-idiotypic antibodies specifically reacted with MOR-hl and not with 26 other multiple organ-reactive monoclonal IgM autoantibodies nor with pooled human IgM (myeloma proteins). The binding of the anti-idiotypic antibodies to MOR-hl was inhibited by both human growth hormone and the 35,000-mol wt protein, which strongly suggests that these antibodies react with epitopes at or near the paratope on MOR-hl. The results of competitive binding experiments revealed that the epitope recognized by 4E6 is distinct from that recognized by 3E5 and 3F6. Using these anti-idiotypic antibodies, lymphocytes and sera from normal individuals were tested for the presence of the 4E6 and 3E5/3F6 idiotopes. By indirect immunofluorescence, the 4E6 idiotope was detected on an average of 1.1% of normal circulating B lymphocytes, and by enzyme-linked immunosorbent assays, the 4E6 and to a lesser extent the 3E5/3F6 idiotopes were found on IgG molecules in sera of normal individuals. In spite of the expression of idiotopes known to be present on MOR-li, no MOR-hl-like antibody activity was detected in normal sera. Examination of sera from patients with several autoimmune diseases failed to show an increased expression of the 4E6 idiotope as compared with normal controls. These data suggest that antiidiotypic antibody 4E6 recognizes a public idiotope, the expression of which is not restricted to autoimmune disease.
Introduction
Idiotypic determinants on antibodies and cells and their recognition by anti-idiotypic antibodies have been given a prominent role in current theories of immunoregulation (1) (2) (3) (4) . The idiotopes expressed on autoantibodies are of particular interest since it has been suggested that autoantibodies may represent failures of, or gaps in, the immunoregulatory network. Recent studies in mice (5) and in humans (6) suggested that certain idiotypes are closely associated with particular autoimmune disorders. It also has been speculated that a limited number of families of immunoglobulins may be involved in autoimmunity (7) . Ifthis turns out to be the case, then anti-idiotypic antibodies may serve as useful probes to quantitate the level of expression of idiotopes in both normal individuals and patients.
Recently we prepared a hybridoma secreting a human monoclonal autoantibody, designated MOR-h 1 (multiple organreactive human 1)' (8) . This antibody (IgM-K) reacts with antigens in several different organs including the pituitary, thyroid, pancreas, and stomach. Using an MOR-h 1 immunoaffinity column we have isolated the autoantigens (i.e., 35 ,000 and 21,000-mol wt proteins) with which this autoantibody reacts. The 35,000-molwt protein is present in the pituitary, thyroid, and stomach; and the 21,000-mol wt protein, which was shown to be human growth hormone (hGH) , is found only in the pituitary. We now report the preparation and characterization ofthree monoclonal antibodies directed against idiotypic determinants at or near the paratope of MOR-h 1. Using these anti-idiotypic antibodies we have studied the expression of the corresponding idiotopes on immunoglobulins in the sera of normal individuals and patients with autoimmune diseases.
Methods
Human monoclonal autoantibodies. The procedure for the preparation of MOR-h 1 and 26 other human monoclonal multiple organ-reactive (MOR) antibodies has already been described (8) (9) . All of these autoantibodies are of the IgM class. Some of these antibodies were prepared by fusing human peripheral B lymphocytes with either human or mouse myeloma cells (8) . Others were prepared by immortalizing peripheral B lymphocytes with Epstein-Barr virus (9) .
Purification of MOR-hi. MOR-hI was purified using an immunoaffinity column, which was prepared by coupling the IgG fraction of sheep anti-human IgM to CNBr-activated Sepharose4B (Pharmacia Fine Chemicals, Piscataway, NJ) as previously described (10). The adsorbed MOR-h 1 was eluted with 0.1 M glycine-HCl (pH 2.5); the pH of the eluate was adjusted to 7.5 before exhaustive dialysis against deionized water, and the material was lyophilized. The purity of MOR-hl was tested by SDS-polyacrylamide gel electrophoresis, and only two bands having the apparent molecular weights of u-and K-chains were detected. The purified MOR-h 1 was also checked for immunological reactivity with synthetic hGH (kindly provided by Genentech, Inc., South San Francisco, CA) and a 35,000-mol wt polypeptide (from human gastric mucosa) by employing an enzyme-linked immunosorbent assay (ELISA) as described earlier (10).
Preparation, screening, and purification ofmonoclonal anti-idiotypic antibodies. Balb/c AnN mice received five weekly, intraperitoneal injections of 100 Ag of affinity-purified MOR-hl . 3 d after the last injection, splenic lymphocytes were fused with P3653 Ag8 myeloma cells using 1. Abbreviations used in this paper: ELISA, enzyme-linked immunosorbent assay; FITC, fluorescein isothiocyanate; hGH, human growth hormone; IDDM, insulin-dependent diabetes mellitus; MOR, multiple organ-reactive; MOR-h 1, multiple organ-reactive human 1 autoantibody; RIA, radioimmunoassay; SLE, systemic lupus erythematosus; TRITC, tetramethylrhodamine isothiocyanate. 50%o polyethylene glycol at neutral pH, essentially as described by Kohler and Milstein (I 1). The fused cells were plated in 96-well tissue culture plates and incubated at 370C. Supernatants from cultures grown to confluency were initially screened for anti-MOR-hl and anti-human IgM antibody by ELISA in which Immulon II plates (Dynatech Laboratories, Alexandria, VA) were coated with either MOR-hl or pooled human myeloma IgM. The bound monoclonal IgG was detected using peroxidase-labeled goat anti-mouse -y-chain-specific antibodies. The positive wells showing reactivity with MOR-h 1, but not with pooled human IgM, were cloned using the end point dilution method (12) . The three hybridomas thus obtained were designated 4E6, 3E5, and 3F6.
Immunoreagents. All Radioiodination ofantibodies and solid-phase radioimmunoassays (RIAs). Affinity-purified monoclonal antibodies were iodinated by a modification of the chloramine T method (13). The reaction mixture was then chromatographed on a Sephadex G-25M column (Pharmacia Fine Chemicals) to separate the protein from free radioiodine. The iodinated proteins were then dialyzed overnight against PBS at 40C, and were tested for their immunological reactivity in a solid-phase RIA. At least 90% of the input counts per minute (cpm) bound to MOR-hl, while only 3-5% ofthe input cpm reacted with gelatin-coated wells which served as the negative control.
For Detection by ELISA of4E6, 3E5, and 3F6 idiotopes in human sera.
Human sera diluted to 1:10 with PBS containing 2% BSA and 0.05% Tween-20 were added to wells that had been coated with I Mg/well of affinity-purified 4E6, 3E5, 3F6, or MOPC-21, and the plates were incubated overnight at 4VC. After washing, the plates were incubated for 5 h at room temperature or overnight at 4VC with peroxidase-conjugated goat anti-human IgG (y-chain-specific) previously absorbed with both MOPC-2 1 and the appropriate anti-idiotypic antibody. After washing the substrate was added and the OD492 of each sample was measured.
Pilot experiments with peroxidase-conjugated goat anti-human IgM (Mchain-specific) yielded high background activity preventing its use to reliably detect the 4E6, 3E5, and 3F6 idiotopes on human IgM in sera.
Results
Preparation of monoclonal anti-idiotypic antibodies against MOR-hI and their reactivities with human monoclonal antibod- clonal anti-idiotypic antibody, 3F6, was used (Fig. 2 B) . In this case, hGH and the 35,000-mol wt protein inhibited the binding of MOR-h 1 to 3F6 over an even greater range of ligand con- centrations. Taken together, these experiments show that both 4E6 and 3F6 are ligand-inhibitable. Evidence for ligand inhibition was also obtained in a solidphase RIA in which the order ofadding the reagents was reversed. Plates were coated with MOR-h 1, incubated with varying concentrations of hGH, and then the binding of '251-labeled 4E6, 3F6, and polyclonal anti-human IgM was measured. As seen in Fig. 3 the binding of the anti-idiotypic antibodies, but not polyclonal anti-human IgM was inhibited. ' Inhibition of binding of hGH to MOR-hi by anti-idiotypic (jg/ml) nentech, Inc., South San Francisco, CA) was added to each well and incubated as described in Methods. After washing, 0.1 ml of rabbit anti-hGH serum (kindly provided by the National Pituitary Agency, Baltimore, MD) diluted 1:2,000 was added to each well. Rabbit IgG binding to hGH was detected by peroxidase-conjugated goat anti-rabbit IgG and the percent inhibition of hGH-binding was then calculated. Maximum binding (100%) corresponded to -1,600 OD492 (X 104) and nonspecific binding (0%) was always <50 OD492 (X 104).
antibody 4E6. If 4E6 is specific for an epitope located at the antigen binding site on MOR-hl, then the binding of hGH to MOR-h 1 should be inhibitable by the anti-idiotypic antibody. Fig. 4 shows that 4E6 blocks the binding of hGH to MOR-h 1, whereas a control mouse monoclonal IgG antibody had no effect. Together with data from Figs. 2 and 3, these results show that anti-idiotypic antibody 4E6 is directed against a site at or near the paratope on MOR-h 1.
Monoclonal anti-idiotypic antibodies recognize diferent epitopes on MOR-hi. The possibility that the different anti-idiotypic antibodies might be recognizing different epitopes was evaluated in blocking experiments. As shown in Fig. 5 A, the binding of '251I-labeled 4E6 to MOR-h 1 was inhibited by unlabeled 4E6, but not by 3E5 or 3F6. In contrast, the binding of '251I-labeled 3E5 and '25I-labeled 3F6 to MOR-h 1 was inhibited by both 3E5 and 3F6, but not by 4E6 (Fig. 5 B and C, respectively) . Thus antibody 4E6 recognizes an epitope on MOR-h 1 that is different from that recognized by 3E5 and 3F6, whereas 3E5 and 3F6 appear to be recognizing the same epitope on the MOR-h 1 molecule.
Detection of4E6 idiotope-bearing B lymphocytes in peripheral blood. Having characterized the monoclonal anti-idiotypic antibodies, we wanted to see if the idiotopes with which they reacted were present on immunoglobulin-bearing B cells. Peripheral blood B lymphocytes were examined for the presence of4E6 idiotope-bearing B cells by indirect immunofluorescence with anti-idiotypic antibody 4E6. From each individual at least 500 surface immunoglobulin-bearing cells were counted. In 13 out of 14 individuals (Table II) , between 0.2 and 3.0% of the B lymphocytes expressed the 4E6 idiotope. Neither MOPC-2 1 nor sheep anti-mouse IgG stained any of the human B cells.
Detection of 4E6 idiotope-bearing immunoglobulins in human sera. Since up to 3% of B cells from normal individuals were found to bear the 4E6 idiotope, sera from normal individuals were tested for the presence of this idiotope. Fig. 6 shows that close to 85% of 130 human sera reacted with anti-idiotypic antibody 4E6 (i.e., 2 SD above control). Considerable quantitative differences, however, were found among individuals. In the same individual, expression of the 4E6 idiotope remained fairly constant with time (Fig. 7) .
Comparison ofthe expression of4E6 and 3E5/3F6 idiotopes in human sera. The presence ofthe 4E6 idiotope in human sera raised the question as to whether the 3E5 and 3F6 idiotopes also were expressed. Plates were coated with equal concentrations (1 jig/well) of the anti-idiotypic antibodies (4E6, 3E5, and 3F6) and then incubated with MOR-h I or a panel of normal human sera. As seen in Fig. 8 , MOR-h 1 reacted to approximately the same extent with all three anti-idiotypic antibodies. The panel of human sera also reacted with anti-idiotypic antibodies 3E5 and 3F6, but to a much lesser extent than with 4E6. One possible explanation for the differences in reactivity is that the 4E6 idiotope may be present on molecules that do not always possess the 3E5 and 3F6 idiotopes.
Sera positive for the 4E6 idiotope do not react with hGH, 35,000-mol wt protein, or human tissues. The widespread expression of the 4E6 idiotope suggested that at least some sera might contain immunoglobulins bearing paratopes similar in reactivity to MOR-h 1. Five sera that showed different degrees of expression of the 4E6 idiotope were tested for their ability to react with hGH, the 35,000-mol wt protein, and sections ofnormal human tissues. As seen in Table III , none ofthe sera showed appreciable reactivity with any ofthe antigens tested. In addition, we tested the ability of different concentrations (from 1 Ug to 1 mg/ml) of hGH to inhibit the binding of these sera to 4E6-coated wells in a competitive inhibition assay. hGH inhibited the binding of MOR-hl to 4E6 in a concentration-dependent manner, but failed to significantly inhibit the binding of these sera to 4E6 (results not shown).
Expression ofthe 4E6 idiotope in patients with autoimmune disorders. Because the MOR-h 1 hybridoma was originally prepared from the lymphocytes ofa patient with insulin-dependent diabetes mellitus (IDDM) and because MOR-h I reacts with autoantigens, we wanted to see if the 4E6 idiotope might be expressed to a greater extent in sera from patients with autoimmune diseases than in sera from normal individuals. clonal MOR autoantibodies nor with pooled human myeloma IgM. Blocking experiments clearly demonstrated that the interaction of purified hGH and the 35,000-mol wt protein with 1.0 patients with only Hashimoto's thyroiditis, and 47 patients with rheumatological disorders (predominantly systemic lupus erythematosus, SLE). As shown in Fig. 9 , except for a few unusually high values for sera from patients with both IDDM and thyroiditis, no discernible differences were detected among the groups of sera. We have generated three murine monoclonal anti-idiotypic antibodies against a human monoclonal autoantibody (MOR-h 1) that reacts with multiple organs (8, 10) . It is generally accepted that an anti-idiotypic antibody is directed against the paratope if it is ligand-inhibitable (16, 17) . Our anti-idiotypic antibodies reacted specifically with MOR-h 1, but not with 26 other mono- (Fig. 5) . Antibody 4E6 defines an idiotypic determinant on MOR-h 1 which is clearly distinct from the site(s) recognized by antibodies 3E5 and 3F6. Since antibodies 3E5 and 3F6 compete with each other, it appears that they may be recognizing the same idiotope which we have designated the 3E5/3F6 idiotope. On immunoglobulin molecules in human sera, in contrast to MOR-h 1, the 4E6 idiotope appears to be expressed independently of the 3E5/3F6 idiotope (Fig. 8) .
Other experiments were carried out in an attempt to further characterize the anti-idiotypic antibodies. Since monoclonal autoantibody MOR-h 1 (idiotypic antibody-Ab I) reacts with hGH and since some anti-idiotypic antibodies (Ab2) are internal images of the paratope with which they react (18-21), we tested anti-idiotypic antibody 4E6 for its ability to bind to hGH receptors. Even at a high concentration, antibody 4E6 (1 mg/ml) failed to inhibit the binding of growth hormone to its receptor on IM-9 cells (K. Essani, unpublished observations) (22) . Others have shown that immunization with "internal image" anti-idiotypic antibodies yields anti-anti-idiotypic antibodies (Ab3), some of which can bind the antigen recognized by the original antibody (Abl) (23) (24) (25) . Preliminary experiments indicate that rabbits immunized with antibody 4E6 acquire MOR-hI antibody activity in their sera (K. Essani and J. Satoh, unpublished observations). Having characterized the 4E6 anti-idiotypic antibody, we used it to study the expression of the 4E6 idiotope on human B lymphocytes. Our experiments revealed that the 4E6 idiotope is expressed on an average of 1.1% of normal B lymphocytes. This unexpectedly high frequency suggests that the 4E6 idiotope is expressed not only on B lymphocytes secreting MOR-hl but also on lymphocytes with other specificities. Moreover, the majority of normal sera contained 4E6-idiotope bearing immunoglobulins in greater or lesser quantities. Despite the presence of the 4E6 idiotope, these sera did not possess MOR-h 1-like antibody activity when tested against hGH, the 35,000-mol wt protein, or human tissues known to react with MOR-h 1. In addition, in a competition assay, hGH failed to inhibit the binding of human sera to 4E6. Taken together, the data suggest that the 4E6 idiotope represents a public specificity on immunoglobulins and is not limited to just MOR-h 1.
Our findings are consistent with the idea that idiotopes present on autoantibodies are not necessarily restricted to antibodies with the same antigen-binding specificity (26) (27) (28) . In fact, antiidiotypic antibodies are known to cross-react with other immunoglobulins at sites not located at or near the antigen-binding domain (29, 30) and even at sites on nonimmunoglobulin mol-1654 Essani, Satoh, Prabhakar, McClintock, and Notkins *0 :
ecules (31) . In this connection, Datta et al. (28) reported that normal mice without detectable amounts ofanti-DNA antibody in their sera, expressed idiotopes that reacted with anti-idiotypic antibodies raised against anti-DNA antibodies. These idiotopes were expressed on both DNA-binding and non-DNA-binding immunoglobulins in the sera of normal mice. Anti-idiotypic antibodies (Ab2) also may recognize idiotopes on the parallel set of immunoglobulins (Ab3) which may not bind to the antigen that induces Ab 1. In some cases, these idiotopes may be involved in immune regulation (1, 2) . It has been suggested that anti-idiotypic antibodies might serve as probes for detecting idiotopes that might be specifically expressed in certain autoimmune diseases (28, (32) (33) (34) (35) . It is clear, however, from both the present work and recent studies from other laboratories (28, 35 ) that idiotypic markers thought to be related to autoimmune diseases are expressed in normal individuals and that antibodies bearing these markers do not necessarily have the ability to bind autoantigens. This raises a number of fundamental questions about the clinical usefulness of anti-idiotypic antibodies as probes to study autoimmune diseases. First, do all patients with a specific autoimmune disease, or at risk of developing that disease, express the same idiotope? Second, is the specific monoclonal antibody used to make the antiidiotypic antibody present and active in the disease or is it simply part of the normal B cell repertoire (36)? Third, is the idiotope of interest expressed only on autoantibodies characteristic of that disease or is it more generally expressed and present on otherwise unrelated molecules? Ifthe former, its expression may be easily quantitated and correlated with clinical disease activity. Ifthe latter, the background reactivity may preclude meaningful quantitation. Perhaps some of these potential problems can be resolved, at least in part, by developing a large panel of antiidiotypic antibodies directed against a spectrum of disease-specific monoclonal autoantibodies.
